Keyphrases
Adalimumab
20%
Biological Agents
100%
Clinical Practice Guidelines
100%
Consensus Statement
100%
Development Method
20%
Disease-modifying Antirheumatic Drugs (DMARDs)
20%
Embase
20%
Etanercept
20%
Evaluation Criteria
20%
Evaluation Instrument
20%
Evaluation Score
20%
Government Agencies
20%
Guideline Recommendations
20%
Infliximab
20%
MEDLINE
20%
Patient Assessment
20%
Patient Management
20%
Quality Appraisal
100%
Research Criteria
20%
Rheumatoid Arthritis
100%
Rheumatoid Arthritis Treatment
40%
Rheumatology
20%
Stakeholder Participation
20%
Tumor Necrosis Factor Antagonist
40%
Nursing and Health Professions
Adalimumab
6%
Biological Product
100%
Disease Modifying Antirheumatic Drug
6%
Embase
6%
Etanercept
6%
Independent Reviewer
6%
Inflammatory Arthritis
100%
Infliximab
6%
Medline
6%
Patient Assessment
6%
Patient Management
6%
Practice Guideline
100%
Rheumatoid Arthritis
100%
Systematic Review
100%
Tumor Necrosis Factor
13%